Primary endpoint
SE, depressive symptoms
Patients treated with zuranolone+ADT demonstrated a statistically significant improvement in depressive symptoms at D3 compared with those who received placebo+ADT, as assessed by CFB in HAMD-17 total score (least squares [LS] mean [standard error (SE)] CFB, −8.9 [0.39] vs −7.0 [0.38]; LS mean difference [SE] of −1.9 [0.55]; 